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ABSTRACT To fabricate quantum dot arrays with programmable periodicity, functionalized DNA origami nanotubes were developed.
Selected DNA staple strands were biotin-labeled to form periodic binding sites for streptavidin-conjugated quantum dots. Successful
formation of arrays with periods of 43 and 71 nm demonstrates precise, programmable, large-scale nanoparticle patterning; however,
limitations in array periodicity were also observed. Statistical analysis of AFM images revealed evidence for steric hindrance or site
bridging that limited the minimum array periodicity.
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T
he ability to precisely pattern nanoparticles is es-
sential for realizing the potential of nanoelectronic
and nanoplasmonic devices.
1-3 Over the past de-
cade, DNA oligonucleotides have been programmed to
aggregate,
4,5 crystallize,
6,7 and self-assemble into spatially
discrete assemblies
8-13 and linear arrays.
14-16 DNA nano-
technology offers a compelling approach toward program-
mable nanoparticle patterning.
17-20 By implementing basic
design rules, DNA can be used to form complex nanostruc-
tures using the methods of either tiled DNA motifs or DNA
origami.
21-27 When functionalized, these nanostructures
can serve as two-dimensional
28-36 and three-dimensional
37
nanoparticle scaffolds. Several groups have reported suc-
cessful attachment of semiconductor quantum dots (QDs)
tofunctionalizedDNA.
10,33,38Sharmaetal.recentlyreported
the fabrication of periodic QD arrays formed by tiling DNA
motifs.
33 While tiling methods have the ability to create
highly ordered complex arrays, they tend to create continu-
ous sheets; the boundaries of which are not well controlled.
Presented here is a method of fabricating nanoparticle
arrays with controlled periodicity using three-dimensional,
six-helix DNA origami nanotubes. DNA origami nanotubes
ofpredetermineddimensionswereusedtopreciselyarrange
nanoparticles by incorporating binding sites along the axis
of the nanotube using biotin-labeled staple strands. The
unique sequence of each staple strand permits precise
spatial control and modular design of periodic or aperiodic
binding sites. The three-dimensional DNA origami nano-
tubes provide a rigid structure for nanoparticle attachment
in solution. Additionally, the extension of the DNA nano-
tubes into networks via dimerization, polymerization, or
branching offers controlled fabrication of more complex
nanoparticle structures.
The DNA origami nanotubes used in this research were
designed using the principles reported by Mathieu et al.
39
and Douglas et al.
40 where the single-stranded M13mp18
DNA molecule was folded into a six-helix nanotube bundle
using the DNA origami method developed by Rothemund.
25
The design reported here uses 170 unique staple strands to
fold the single-stranded M13mp18 scaffold, resulting in DNA
nanotubes with blunt ends that do not dimerize. The nano-
tube design is illustrated and described in detail in the
Supporting Information S1. Staple strands include 9 strands
with 69 nucleotides, 9 strands with 35 nucleotides, and 152
strandswith42nucleotides(seeSupportingInformationS2).
The DNA nanotubes were designed to be 412 nm in length
and 6 nm in diameter. To incorporate nanoparticle binding
sites, prior to nanotube synthesis, selected staple strands
were extended with a 2.2 nm tether consisting of 5 thymine
nucleotides and modiﬁed with biotin at the 3′ end. The
resulting DNA nanotubes possessed precisely spaced biotin
binding sites for controlled positioning of streptavidin-
conjugated nanoparticles along the length of the nanotube
(see Supporting Information S3).
To test controlled nanoparticle patterning, four distinct
DNA nanotubes were synthesized with evenly spaced bind-
ing sites designed to attach 5, 9, 15, or 29 streptavidin-
conjugated nanoparticles to form arrays with periodicities
of71,43,29,or14nm,respectively.Thebiotin-labeledDNA
nanotubes were designed by functionalizing the appropriate
staple strands, as described above. The nanotubes were
synthesized by combining M13mp18 viral DNA (New En-
gland Biolabs) with unmodiﬁed and biotin-labeled staple
strands (Integrated DNA Technologies) in a molar ratio of
1:10:10 in a solution of 1 × TAE, Mg2+ (40 mM tris, 20 mM
acetic acid, 2 mM ethylenediaminetetracetic acid (EDTA),
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acetate tetrahydrate, and laboratory grade water (Milli-Q
Water, Millipore) were purchased from Sigma Aldrich. All
DNA strands were used without further puriﬁcation. To form
nanotubes, the DNA solution was thermally annealed at 90
°C for 20 min, then cooled to 20 °C at ∼1 °C per minute
using a thermal cycler (Mastercycler, Eppendorf). After the
nanotubes were synthesized, the solution was centrifuged
using a centrifugal ﬁlter (100 000 molecular weight cut off)
at 500 g for 15 min to remove excess staple strands and
small, unbound DNA fragments.
Successful formation of biotin-labeled DNA nanotubes
was conﬁrmed via atomic force microscopy (AFM). During
sample preparation, 5 µL of DNA nanotube solution was
dispersed onto freshly cleaved V-4 grade mica with 20 µL
of 1 × TAE, Mg2+ buffer and allowed to adsorb onto the
surface for 5 min. Then, the surface was washed with Milli-Q
water and dried with compressed air. Imaging of function-
alized nanotubes was performed using AFM (Multimode
Picoforce with a Nanoscope IV controller, Veeco Metrology)
under ambient conditions in AC mode using silicon cantilever-
based tips (PPP-NCH, Nanosensors). Cantilevers had a nomi-
nal spring constant of 42 N/m with a range of 10-130 N/m.
To validate the linearity, stability, and accuracy of the
piezoelectric scanner, the AFM was calibrated using (1) a
surfacetopographyreference(STR)withprecisionfabricated
silicon dioxide rectangular features (VLSI Standards), and (2)
the atomic step height of freshly cleaved, ZYH grade, highly
ordered pyrolytic graphite (HOPG, Veeco Metrology) (see
Supporting Information S4).
Figure 1 shows DNA origami nanotubes with nine biotin
binding sites as synthesized (a-e), after functionalization
with streptavidin (f-j), and after functionalization with
streptavidin-conjugated quantum dots (k-o). Figure 1a il-
lustrates the biotin-labeled nanotube structure, while panels
b and c show low- and high-magniﬁcation AFM height
images, respectively. The dashed line in panel c indicates
the location of the cross-sectional height proﬁle in panel d.
From this proﬁle, a nanotube height of ∼2.6 nm is mea-
sured. When measured under various imaging conditions,
the mean nanotube height ranged from 3.5 ( 0.1 to 1.7 (
0.4 nm (see Supporting Information S5). The axial proﬁle
shown in panel e emphasizes relative height variations along
the nanotube length (see Supporting Information S6). The
mean nanotube length was measured to be 436 ( 14 nm
from 100 samples and was independent of the imaging
conditions. The DNA origami nanotubes were designed to
have a circular cross-section equivalent to 3 double helices
(i.e., 6 nm)
39 with an expected length of 412 nm. While the
nanotube length is in agreement with the expected value,
the height is less than the expected diameter. According to
Douglas et al., the diameter of DNA nanotubes with six
helices was ∼7 ( 2 nm using transmission electron micros-
copy (TEM).
40 Sources of deviation may include the nano-
tube collapsing onto the mica surface because of surface van
der Waals forces,
41,42 capillary effects encountered when
imaging in ambient conditions,
41 and compressive forces
during AFM imaging
43-45 (see Supporting Information S5).
For example, reduced AFM height proﬁles for soft biological
samples have been reported in multiple studies.
41,46,47
Once biotin-labeled DNA nanotubes were veriﬁed via
AFM, the accessibility and reactivity of the biotin attachment
sites were tested by combininga1n Msolution of biotin-
labeled nanotubes with pure, lyophilized streptavidin pur-
chased from Sigma Aldrich that was resuspended in Milli-Q
water at 200 nM. The components were allowed to react for
2 h at room temperature. The reacted nanotubes were
dispersed onto a freshly cleaved mica surface and dried as
described above. Figure 1f illustrates the biotin-labeled DNA
nanotubes with attached streptavidin. The successful attach-
ment of nine streptavidin molecules is clearly observed by
comparison of the high-magniﬁcation AFM images without
streptavidin in panel c and with streptavidin in panel h. The
cross-sectional proﬁle in panel i, obtained at an apparent
streptavidin site, reveals a height increase of ∼0.5 nm
relative to the nanotube shown in panel d. The axial proﬁle
in panel j clearly displays nine peaks with a periodicity of
45 nm, very close to the expected value of 43 nm.
While the measured height increase at a streptavidin site
was ∼0.5 nm, the mean height of free streptavidin, dis-
persed onto freshly cleaved mica, was measured to range
from 2.3 ( 0.5 to 0.7 ( 0.2 nm under various imaging
conditions (see Supporting Information S5). Although X-ray
analysis of dehydrated streptavidin crystals indicated a
thickness of 4.6 nm,
48-51 Weisenhorn et al. imaged strepta-
vidin under different AFM contact forces and demonstrated
that the maximum height varied between 1.12, 0.65, and
0.25 nm at 30, 60, and 150 pN, respectively.
44 Thus, the
streptavidin heights measured here are consistent with
previous studies.
CdSe/ZnS core/shell streptavidin-conjugated quantum
dots(Qdot585,Invitrogen),hereafterreferredtoasquantum
dots, with an average diameter of 15-20 nm were chosen
totestnanoparticleattachment.Toensureahighattachment
yield,a1n Msolution of functionalized DNA nanotubes was
combined at room temperature with a 200 nM solution of
quantum dots for 2 h. The reacted DNA nanotubes with
attached quantum dots were dispersed onto a mica surface
and dried as described above. Figure 1k illustrates the
attachment of the quantum dots to the biotin-labeled DNA
nanotubes. Figure 1l,m respectively shows low- and high-
magniﬁcation AFM height images of the DNA nanotubes
with attached quantum dots. When compared to panels c
andh,quantumdotsattachtobiotin-labeledDNAnanotubes
with the same periodic spacing. Additionally, the cross-
sectional proﬁle across an apparent quantum dot in panel n
yields a height of 5.5 nm, nearly twice the measured height
of the nanotube with no attached particles. The mean height
of free quantum dots, dispersed onto freshly cleaved mica,
was measured to range from 5.5 ( 0.6 to 4.7 ( 0.7 nm
© 2010 American Chemical Society 3368 DOI: 10.1021/nl101079u | Nano Lett. 2010, 10, 3367-–3372under various imaging conditions (see Supporting Informa-
tion S5). Although the diameter of the streptavidin-conju-
gated quantum dots is ∼20 nm in solution according to
manufacturer speciﬁcations, the AFM height measurements
of the dehydrated quantum dots correspond to the ap-
proximatediameteroftheCdSe/ZnSquantumdotcore/shell,
as measured by TEM (see Supporting Information S7). Thus,
with the chosen AFM imaging conditions the dehydrated
streptavidin and polymer layer contributed very little to the
measured height of the conjugated nanoparticle. The axial
proﬁle in panel o again shows nine equally spaced peaks
with a periodicity of 49 nm.
To illustrate the ﬂexibility of the design and conﬁrm
control over nanoparticle attachment, functionalized DNA
nanotubes were synthesized with 5, 9, 15, and 29 biotin
attachment sites to enable the formation of quantum dot
arrays with periodicities of 71, 43, 29, and 14 nm, respec-
tively.Thesenanotubeswerereactedwithquantumdotsand
dispersed onto mica substrates as in the manner described
above. Figure 2 shows high-magniﬁcation height images of
quantum dots attached to DNA nanotubes with (a) 5, (b) 9,
(c) 15, and (d) 29 biotin binding sites. Successful attachment
to each biotin binding site was observed for nanotubes with
5 or 9 available sites; however, attached quantum dots were
not observed at each site for nanotubes with 15 or 29
available sites. The average quantum dot spacings were
measured to be approximately 71 ( 3, 49 ( 4, 46 ( 5, and
31 ( 4 nm for nanotubes with 5, 9, 15, and 29 available
biotin binding sites, respectively. The measured spacings for
5 and 9 binding sites agree well with the predicted periods
of 71 and 43 nm. However, the arrays seen in Figure 2c,d
formed with a reduced number of quantum dots and,
FIGURE 1. Schematics, AFM images at low magniﬁcation (upper) and high magniﬁcation (lower), and cross-sectional (upper) and axial (lower)
height proﬁles of functionalized DNA origami nanotubes with nine biotin binding sites with (a-e) no attached nanoparticles; (f-j) attached
streptavidin; and (k-o) attached streptavidin-conjugated quantum dots. The dashed lines in the high-magniﬁcation AFM images indicate the
location of the cross-sectional proﬁles. Axial proﬁles represent the average of multiple proﬁles across the width of the nanotube (see Supporting
Information S6).
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14 nm, respectively. Additionally, successful attachment of
15 quantum dots to a DNA nanotube functionalized with 29
biotin binding sites was observed by TEM (see Supporting
Information S7). The average quantum dot spacing was
measured to be 28 ( 7 nm, in agreement with the average
spacing measured by AFM.
In Figure 2, only 10 quantum dots were attached to the
nanotube with 15 available sites, and only 17 quantum dots
were attached to the nanotube with 29 available sites. It is
also noted that for the cases of 15 and 29 binding sites, the
attached quantum dots alternate from one side of the DNA
nanotube to the other with a greater frequency than for the
cases of 5 or 9 binding sites. Several factors, hereafter
referred to as binding obstructions, that may limit quantum
dot attachment include (1) steric hindrance between quan-
tum dots, (2) quantum dots bridging multiple biotin-labeled
staple strands, (3) site poisoning of biotin-labeled staple
strands by free streptavidin, (4) biotin-labeled staple strands
that are missing their biotin modiﬁcation, and (5) trapping
of tethered biotin inside the DNA nanotube. Based on the
design of the DNA nanotubes, 15 and 29 binding sites
correspond to periodicities of 29 and 14 nm, respectively.
AFM measurements of the center-to-center quantum dot
separation show a minimum separation distance of 20 nm,
which we interpret as the effective diameter of the quantum
dots in solution (see Supporting Information S8). Thus, steric
hindrance is expected for an array periodicity of 20 nm or
less (e.g., 14 nm).
To further assess the degree of successful quantum dot
attachment, Figure 3 shows histograms of the number of
quantum dots attached to DNA nanotubes labeled with (a)
5, (b) 9, (c) 15, and (d) 29 biotin binding sites. The data for
the histograms were compiled from AFM image analysis for
over 225 separate nanotubes for each case (see Supporting
Information S9). For the cases of 5 and 9 available binding
sites, the histograms are peaked at 4 and 7 successful
attachments, very near the designed number of sites. How-
ever,inthecasesof15and29availablesites,thehistograms
are peaked at 10 and 17 successful attachments, conﬁrming
that attachment to each available binding site is much more
likely for nanotubes functionalized with 5 or 9 binding sites
than for those with 15 or 29. It is also noted that a small
number of nanotubes appeared to have more attached
quantum dots than available binding sites, which we at-
tribute to coincidental alignment of a nanotube with full
attachment and free quantum dots.
Assuming that quantum dot binding events occur with
an equal average attachment probability for each site, the
attachment histograms would be expected to follow a
binomial distribution, P(m), given by
where n is the given number of available biotin binding sites
pernanotubeandmisthenumberofattachedquantumdots
per nanotube.
52 The average attachment probability, p,i s
given by
FIGURE 2. High-magniﬁcation AFM images of streptavidin-conju-
gated quantum dots attached to functionalized DNA origami nano-
tubes with (a) 5 binding sites, 71 nm period; (b) 9 binding sites, 43
nm period; (c) 15 binding sites, 29 nm period; and (d) 29 binding
sites, 14 nm period. All scale bars are 100 nm. Note (c) and (d) have
fewer attached quantum dots than available binding sites. In
addition, the diameter of quantum dots varies between images
because of variation in tip radii between scans.
FIGURE 3. Histograms (bars) and calculated binomial distributions
(lines) for the number of attached quantum dots for DNA nanotubes
with (a) 5, (b) 9, (c) 15, and (d) 29 biotin binding sites. Data for each
histogram were compiled from AFM image analysis for over 225
separate nanotubes, with the exact number, N, shown for each
histogram. The average attachment probabilities, p, used to generate
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tum dots, and the denominator is the total number of
available attachment sites. The average attachment prob-
abilities were calculated using eq 2 from the histogram data
to be 0.77, 0.76, 0.65, and 0.64 for 5, 9, 15, and 29 sites,
respectively. For the case of 5 binding sites, the attachment
probability for pure streptavidin was calculated from histo-
gram data to be 0.79, only slightly higher than for quantum
dot attachment (see Supporting Information S10). Similar
attachment probabilities for pure streptavidin and quantum
dots may indicate biotin-labeled staple strands are missing
their biotin modiﬁcation and/or tethered biotin is trapped
inside the DNA nanotube. The solid lines in Figure 3 plot the
calculated binomial distribution of eq 1 for each case.
Overall, the calculated distributions follow the data well,
conﬁrming equal attachment probability per site. However,
the histograms in Figure 3c,d display a slight shift toward
lower attachment, providing some evidence for steric hin-
drance or site bridging.
For evidence of steric hindrance or bridging, the nearest-
neighborseparationdistances,projectedalongthenanotube
axis, were measured for pairs of bound quantum dots (see
Supporting Information S11). In the absence of steric hin-
drance or site bridging, the nearest-neighbor separation
histograms would be expected to follow a geometric distri-
bution peaked at the designed nanotube binding site peri-
odicity. The geometric distribution, P(l), of nearest-neighbor
separations is given by
where l is the integer number of periods between nearest-
neighbors.
52Histogramsofthenearest-neighborseparations
and the geometric distributions calculated using the average
attachment probabilities p are shown in Figure 4 for each of
the four cases. For each case, measured nearest-neighbor
separation distances were normalized to represent the
number of designed binding site periods between particles.
The data were sorted into bins of width a centered on the
nth period, where a is the designed nanotube periodicity and
n is an integer. Thus, nearest-neighbor separations of less
than a/2 were indicated as a zero separation. For 5 and 9
attachment sites, the nearest-neighbor separation histo-
grams are peaked at the designed binding site periodicity.
However, for 15 and 29 binding sites, the nearest-neighbor
separation histograms are peaked at 2 and 3 periods,
respectively. The calculated geometric distributions match
the data well for the nanotubes with 5 and 9 attachment
sites, but deviate signiﬁcantly for the nanotubes with 15 and
29 sites. Thus, the data may indicate that steric hindrance
orsitebridgingreducethenumberofquantumdotsattached
to the nanotubes.
Functionalized DNA origami nanotubes were designed
with biotin-labeled staple strands spaced evenly along the
axis of the nanotubes. The nanotubes were synthesized and
combined with streptavidin-conjugated quantum dots to
form nanoparticle arrays with controlled periodicities. AFM
images of the synthesized arrays revealed successful attach-
ment of quantum dots at locations along the nanotube axes
thatcorrespondedtoavailablebiotinbindingsites.Statistical
analysis of AFM images indicates that binding obstructions
establish an upper limit on the yield of nanotubes fully
occupied by quantum dots, as indicated by reduced attach-
mentprobabilitiesanddeviationsfromtheexpectednearest-
neighbor distributions for nanotubes with 15 or 29 binding
sites. In addition to steric hindrance between quantum dots
and quantum dots bridging multiple biotin-labeled staple
strands,obstructionsmayinclude(1)sitepoisoningofbiotin-
labeled staple strands by free streptavidin, (2) biotin-labeled
staple strands that are missing their biotin modiﬁcation, and
(3) trapping of tethered biotin inside the DNA nanotube. In
addition, a minimum gap distance was measured between
two streptavidin-conjugated quantum dots, thereby estab-
lishing an important design constraint when fabricating
nanoelectronic and nanoplasmonic devices based on DNA
origami.
Theseresultsprovideapowerfulandconvenientpathway
to control nanoparticle patterning, allowing for self-as-
p ) ∑attached QD
∑available sites
(2)
P(l) ) p(1 - p)
(l-1) (3)
FIGURE 4. Histograms (bars) and calculated geometric distributions
(lines) for nearest-neighbor (N-N) separation of bound quantum dot
pairs for DNA nanotubes with (a) 5, (b) 9, (c) 15, and (d) 29 biotin
binding sites. The numbers of separations, N, measured for each case
are provided in the ﬁgures, along with the average attachment
probabilities, p. N-N separation of zero indicates two nearest
neighbors with a separation less than one-half of a period.
© 2010 American Chemical Society 3371 DOI: 10.1021/nl101079u | Nano Lett. 2010, 10, 3367-–3372sembled fabrication of nanoscale electronic and photonic
devices. Because of the symmetry of DNA origami nano-
tubes and the nonrepeating sequence of the scaffold strand,
it is possible to extend the nanotube functionalization
technique to form aperiodic arrays, as well as three-
dimensional arrays. Considering there are 170 unique staple
strandsthatcanbefunctionalizedbyvariousmeansateither
end, or even within the strand itself, the possibilities for
variationsarevast.Inclusionofnanoparticlesofdifferingsize
and/or differing material is within reach and extended
networks of functionalized DNA origami nanotubes linked
together in two or even three dimensions is plausible.
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